1. Home
  2. PSFE vs RAPT Comparison

PSFE vs RAPT Comparison

Compare PSFE & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paysafe Limited

PSFE

Paysafe Limited

HOLD

Current Price

$8.23

Market Cap

461.4M

ML Signal

HOLD

Logo RAPT Therapeutics Inc.

RAPT

RAPT Therapeutics Inc.

HOLD

Current Price

$35.91

Market Cap

498.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSFE
RAPT
Founded
1996
2015
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
461.4M
498.4M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
PSFE
RAPT
Price
$8.23
$35.91
Analyst Decision
Hold
Strong Buy
Analyst Count
5
10
Target Price
$10.60
$57.00
AVG Volume (30 Days)
606.0K
469.6K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,683,103,000.00
N/A
Revenue This Year
$1.95
N/A
Revenue Next Year
$6.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.43
$5.67
52 Week High
$24.11
$42.39

Technical Indicators

Market Signals
Indicator
PSFE
RAPT
Relative Strength Index (RSI) 47.67 59.12
Support Level $7.68 $31.70
Resistance Level $8.46 $37.75
Average True Range (ATR) 0.37 2.62
MACD 0.12 -0.07
Stochastic Oscillator 56.70 61.33

Price Performance

Historical Comparison
PSFE
RAPT

About PSFE Paysafe Limited

Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company provides payment solutions through three primary lines of business: Integrated Processing, Digital Wallet and eCash Solutions. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.

About RAPT RAPT Therapeutics Inc.

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Share on Social Networks: